Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
SAN FRANCISCO, May 08, 2018 -- Nurix, Inc., a private drug discovery company, today announced the appointment of Dr. Nancy Pryer as the company’s chief development officer. Dr. Pryer will join Nurix’s executive management team to lead the company’s preclinical, translational and clinical drug development efforts.
“We are delighted to welcome Dr. Pryer to Nurix,” said Arthur T. Sands, M.D., Ph.D., chief executive officer of Nurix. “Her extraordinary depth of experience in oncology and drug development broadly will provide great value to Nurix as we advance our breakthrough science into human clinical studies.”
Dr. Pryer joins Nurix from BioMarin Pharmaceutical, where she served as vice president of translational sciences. In that role, she led the company’s efforts in biomarker discovery, bioanalytics, immunogenicity assessment and clinical pharmacology. Prior to joining BioMarin, Dr. Pryer held leadership roles in oncology drug discovery and translational development at Novartis Institutes for Biomedical Research, Raven, SUGEN and Onyx Pharmaceuticals. Dr. Pryer received her Ph.D. in biology from the University of North Carolina, Chapel Hill, and completed post-doctoral work in the lab of Dr. Randy Schekman at the University of California, Berkeley.
“This is an exciting time in the field of protein homeostasis and targeted protein degradation, as years of effort are yielding novel candidate therapeutics for oncology and other unmet medical needs,” said Dr. Pryer. “Throughout my career I’ve been passionate about evaluating drug mechanism of action to develop new therapies for select patient populations. I look forward to working with Arthur and the Nurix team to apply these translational medicine approaches as we move the Nurix pipeline through IND-enabling studies and into the clinic.”
About Nurix
Nurix, Inc. is a leader in the discovery of small molecules that modulate the ubiquitin proteasome system (UPS) to address significant, unmet medical needs. The UPS is a regulatory pathway that controls protein levels, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas. Nurix was founded by internationally-recognized experts in the ubiquitin proteasome field and is funded by leading life science investors Third Rock Ventures and The Column Group. In September 2015, Nurix and Celgene entered into a broad collaboration targeting protein homeostasis for next-generation therapies in oncology, inflammation and immunology. The company is headquartered in San Francisco, California. For more information, please visit http://www.nurix-inc.com.
Media Contact
Sara Zelkovic
LifeSci Public Relations
[email protected]
